Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Objective Many clinical trials of immune checkpoint inhibitors (ICIs) in combination with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) have been initiated, but the conclusions of these trials are not identical. This meta-analysis aimed to comprehensively collect these randomized clinical controlled trials (RCTs) to evaluate the efficacy and safety of ICIs combined with chemotherapy in the first-line treatment of ES-SCLC. Methods We systematically searched PubMed, Embase, and ClinicalTrials databases, to find relevant studies published until October 2022.RevMan 5.4 software was used for statistical analysis. The Cochrane Risk of Bias Tool was adopted to evaluate the risk of bias in the included studies. The primary outcome of this study was overall survival (OS), while the secondary outcomes were progression-free survival (PFS), objective response rate (ORR), all grand AEs (AEs), and ≥ 3 grand adverse events (≥ 3 AEs). Results A total of 780 articles were obtained in the initial examination, which was screened by layer and finally included 8 studies including 3367 patients. Six studies evaluated the efficacy of PD-1/PD-L1 inhibitors (Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Adebrelimab, Serpulimab) combined with chemotherapy, and two studies evaluated the efficacy of CTLA-4 inhibitors (Ipilimumab) in combination with chemotherapy. The results showed that compared to chemotherapy alone, ICIs combined with chemotherapy significantly improved patients’ OS (HR=0.8, 95% CI (0.72-0.85), P<0.05), PFS (HR = 0.72, 95% CI (0.63-0.83), P < 0.05), and ORR(RR=1.08, 95% CI: 1.03-1.13, P<0.05), but patients would experience more any grand AEs and ≥3 grand AEs. Subgroup analysis showed that the PD-1/PD-L1 group performed better than the CTLA-4 group in both efficacy and safety. And ICIs plus chemotherapy significantly improved OS and PFS in patients regardless of age, gender, and performance status. Conclusion The addition of ICIs to chemotherapy resulted in significant improvements in both PFS and OS for patients with ES-SCLC, but patients would experience more AEs.

[1]  J. Bar,et al.  Real-world evidence for immunotherapy in the first line setting in small cell lung cancer. , 2022, Lung cancer.

[2]  Baolan Li,et al.  Abstract CT038: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC: A phase 3 trial , 2022, Cancer Research.

[3]  H. Mann,et al.  Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN , 2022, ESMO open.

[4]  G. Scambia,et al.  Chemotherapy Resistance in Epithelial Ovarian Cancer: Mechanisms and Emerging Treatments. , 2021, Seminars in cancer biology.

[5]  M. Costa.  Twenty-Third Heidelberger Symposium on Cancer Research. , 2021, Seminars in cancer biology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  N. Reinmuth,et al.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Erratum: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. , 2020, CA: a cancer journal for clinicians.

[9]  C. Rudin,et al.  Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  V. Welch,et al.  Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. , 2019, The Cochrane database of systematic reviews.

[11]  Jinming Yu,et al.  Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer , 2019, Journal of Hematology & Oncology.

[12]  Qiming Wang,et al.  Emerging therapies for small cell lung cancer , 2019, Journal of Hematology & Oncology.

[13]  V. Torri,et al.  Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. , 2019, Cancer treatment reviews.

[14]  A. Calles,et al.  The role of immunotherapy in small cell lung cancer , 2019, Clinical and Translational Oncology.

[15]  C. Dive,et al.  Will liquid biopsies improve outcomes for patients with small-cell lung cancer? , 2018, The Lancet. Oncology.

[16]  Paolo A Ascierto,et al.  Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. , 2018, Cancer cell.

[17]  D. Morgensztern,et al.  Treatment advances in small cell lung cancer (SCLC) , 2017, Pharmacology & therapeutics.

[18]  P. Stephens,et al.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers , 2017, Molecular Cancer Therapeutics.

[19]  C. Rudin,et al.  Unravelling the biology of SCLC: implications for therapy , 2017, Nature Reviews Clinical Oncology.

[20]  D. Jäger,et al.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.

[21]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[22]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[23]  Mustafa Saad,et al.  Implications for Therapy , 2016 .

[24]  D. Pardoll.  Cancer and the Immune System: Basic Concepts and Targets for Intervention. , 2015, Seminars in oncology.

[25]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[26]  K. Phan,et al.  Systematic review and meta-analysis: techniques and a guide for the academic surgeon. , 2015, Annals of cardiothoracic surgery.

[27]  M. Socinski,et al.  Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  A. Rossi,et al.  Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[30]  D. Moher,et al.  Nonalcoholic Fatty Liver Disease and Acute Ischemic Stroke , 2010 .

[31]  Minna,et al.  A Small Cell Lung Cancer Genome Reports Complex Tobacco Exposure Signatures Europe Pmc Funders Group , 2022 .

[32]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.

[33]  J. Crowley,et al.  Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Irvin M Modlin,et al.  Bronchopulmonary neuroendocrine tumors , 2008, Cancer.

[35]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.